Clik here to view.
With Actelion’s Acquisition Done, What are the Largest European Biotechs?
With Actelion’s acquisition by J&J, there is room for a new company to take over its spot as Europe’s biggest biotech. We had a look at the new top 5. Early this year, J&J finally sealed the...
View ArticleGalapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year
With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The...
View ArticleClik here to view.
Belgian Biotech Passes Go and May Collect €290M for Arthritis Drug’s Progress
Galapagos has received another tranche of €290M in milestones as Servier exercises its option to develop its osteoarthritis candidate, GLPG1972. Galapagos, the Belgian biotech that made its way onto...
View ArticleClik here to view.
Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market
Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a...
View ArticleClik here to view.
Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model
Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It was when he was studying at the...
View ArticleClik here to view.
More News! French Immuno-oncology Biotech Gets Busy with Partnerships
Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week. OSE opted to expand its alliance with Selexis surrounding cancer...
View ArticleClik here to view.
Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout
Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing...
View ArticleClik here to view.
More News! European Companies Join the Nasdaq Biotech Index
Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week. A horde of European biotechs including Cellectis, Adaptimmune, uniQure, and...
View ArticleInterviews, Reviews and Tops: Our Best Biotech Articles from 2017
We love hearing from our readers, and we listen to what they like! Here are the long reads from our best biotech articles of 2017. We gave you a list of books to read this holiday season, but do you...
View ArticleClik here to view.
Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA
Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies...
View ArticleClik here to view.
Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the...
Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back at the pre-2000 companies to see how...
View ArticleClik here to view.
Morphosys and Galapagos Announce Positive Phase I Results for Atopic...
Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody that could...
View ArticleMore News! New Antibiotics, Biodegradable Bone Implants and Infectious...
Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of more news that didn’t make the cut over the last week. German biotech AiCuris reported positive Phase I results from...
View ArticleGalapagos Reports Promising Phase III Data in Rheumatoid Arthritis
Galapagos and Gilead have reported positive results from a Phase III trial testing Galapagos’ lead drug candidate in patients with rheumatoid arthritis. The clinical trial recruited patients with...
View ArticleClik here to view.
Bridging the Academia-Industry Divide: Lessons from a Serial Biotech...
What does it take to be a successful biotech entrepreneur? I put this and other similar questions to Dinko Valerio, a highly experienced Dutch geneticist turned serial entrepreneur and investor. While...
View ArticleClik here to view.
The Billion-Euro European Biotech Companies in 2018
Here’s the list of the European biotech companies, both public and private, that are worth more than a billion-euro in 2018. European biotech is growing steadily and this year we welcome a few new...
View ArticleGalapagos Nears First Drug Approval with Phase III Success in Rheumatoid...
Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years...
View ArticleClik here to view.
The 8 Best Biotech Companies in Europe’s History
We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and the development of the booming industry that biotech is today. Though the...
View ArticleClik here to view.
Gilead Pays Billions for Access to Galapagos’ Pipeline
Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for...
View ArticleMorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II
Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of...
View Article
